The Ophthalmology Therapeutics Market size in the Middle East and Africa was worth USD 3.04 billion in 2022. It is further estimated to grow at a CAGR of 8.1% and worth USD 4.48 billion by 2027.
Ophthalmology is the science associated with the treatment of eye defects and diseases. Recent advancements in genetics and stem cell biology are progressively boosting the potential for ophthalmology therapeutics.
The growing prevalence of vision impairment drives the Middle East and Africa market for Ophthalmology Therapeutics. Advancements in the field of medicine is also a key factor driving the growth of the market. The increasing geriatric population around the region and an increase in the disposable income of the people are some of the other driving factors for the Ophthalmology Therapeutics Market.
However, limited awareness about the diseases associated with ophthalmology is the key restraint for the market's growth. Uncertain reimbursement policies and stringent regulatory frameworks are some of the other factors restraining the market's growth.
This research report on the MEA Ophthalmology Therapeutics Market has been segmented and sub-segmented into the following categories:
By End User:
Based on end-user, the Hospital segment accounts for the largest share of the market with a percentage share of approximately XX%. At the same time, Diagnostics Centres are the fastest-growing segment with a CAGR of XX%.
Geographically, Middle-East is the largest market for Ophthalmology Therapeutics due to the people's high disposable income. Africa is estimated to be the fastest-growing region with a CAGR of xx% during the forecast period.
Prominent companies leading the MEA Ophthalmology Therapeutics Market are Pfizer Inc., Allergan Inc., Alcon Inc., Merck & co. Inc., Roche Valeant, Regeneron, Santen, Bayer, Senju, Lpath, and Eye Gate Pharmaceuticals.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: firstname.lastname@example.org